INT353110

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.00
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.67
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) cytoplasm (VEGFA)
Anatomy Link Frequency
retina 2
VEGFA (Homo sapiens)
Eo (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 48 5.00 Very Low Very Low Very Low
cva 34 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
eye pain 2 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
ischemia 2 5.00 Very Low Very Low Very Low
Nicotine 2 5.00 Very Low Very Low Very Low
Inflammatory response 2 5.00 Very Low Very Low Very Low
Inflammatory stimuli 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Age-related Macular Degeneration 490 90.00 High High
Sprains And Strains 2 80.56 Quite High
Disease 20 27.72 Quite Low
Ocular Toxicity (including Many Sub-types) 96 5.00 Very Low Very Low Very Low
INFLAMMATION 56 5.00 Very Low Very Low Very Low
Ocular Injury 26 5.00 Very Low Very Low Very Low
Nicotine Addiction 24 5.00 Very Low Very Low Very Low
Ocular Hypertension 24 5.00 Very Low Very Low Very Low
Pressure And Volume Under Development 16 5.00 Very Low Very Low Very Low
Geographic Atrophy 14 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A rational drug design process was utilized with the following desirable qualities for an effective ocular antiangiogenic therapeutic: local deliverability into the eye, ability to penetrate through the retina to the sub-RPE space, high affinity for its target (all forms of VEGF-A), and safety and tolerability with minimal systemic exposure.
VEGF Binding (affinity) of eye in retina
1) Confidence 0.00 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012443 Disease Relevance 0.34 Pain Relevance 0
A rational drug design process was utilized with the following desirable qualities for an effective ocular antiangiogenic therapeutic: local deliverability into the eye, ability to penetrate through the retina to the sub-RPE space, high affinity for its target (all forms of VEGF-A), and safety and tolerability with minimal systemic exposure.
VEGF Binding (affinity) of eye in retina
2) Confidence 0.00 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012443 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox